Travere Therapeutics, based in San Diego, focuses on developing therapies for rare kidney and metabolic diseases, with products like FILSPARI for IgAN and Pegtibatinase for classical homocystinuria. Founded in 2003, the company employs 380 people and also offers Thiola for cystinuria.
Travere Therapeutics (TVTX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Travere Therapeutics's actual EPS was -$0.14, beating the estimate of -$0.30 per share, resulting in a 53.90% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
